首頁 > 市場調查報告書 > 製藥

DDS

市場調查報告書

商品編碼

1907955

頭孢他啶-阿維巴坦市場按類型、適應症、劑型、藥物類型、最終用戶、分銷管道和地區分類

Ceftazidime Avibactam Market, By Type, By Indication, By Dosage Form, By Drug Type, By End User, By Distribution Channel, By Geography

出版日期: 2025年12月11日 | 出版商:

Coherent Market Insights | 英文 168 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

頭孢他啶-阿維巴坦市場預計在 2025 年達到 34.3 億美元，預計到 2032 年將達到 59.2 億美元，2025 年至 2032 年的複合年成長率為 8.1%。

分析範圍		分析詳情
基準年	2024	市場規模（2025 年）	34.3億美元
效能數據	2020-2024	預測期	2025-2032
預測期（2025-2032 年）複合年成長率	8.10%	預計金額（2032 年）	59.2億美元

全球頭孢他啶-阿維巴坦市場是先進抗菌治療的重要組成部分，旨在應對日益嚴峻的多重抗藥性感染疾病挑戰。頭孢他啶-阿維巴坦是一種新型複方抗生素，由第三代頭孢菌素類抗生素頭孢他啶和BETA-內醯胺酶抑制劑阿維巴坦組成，已成為治療複雜性腹腔感染疾病、複雜性尿道感染以及革蘭氏陰性菌引起的醫院獲得性肺炎的突破性治療選擇。

這種創新療法組合已證實能有效對抗碳青黴烯類抗藥性腸桿菌科細菌 (CRE) 和其他頻譜BETA-內醯胺酶產生菌，成為對抗抗菌藥物抗藥性的重要工具。該產品以多種劑型、劑量規格和通路供應，包括醫院藥房、零售藥房和線上平台。由於醫療相關感染疾病的增加、抗菌藥物管理計劃意識的提高以及對抗生素研發投入的不斷成長，頭孢他啶-阿維巴坦市場在全球範圍內持續擴張。主要市場參與企業正致力於建立策略合作夥伴關係、獲得監管部門核准以及製定市場滲透策略，以滿足治療抗藥性病菌感染的巨大未滿足需求，尤其是在加護病房和免疫力缺乏患者群體中。

市場動態

全球頭孢他啶和阿維巴坦市場的主要驅動力是全球多重抗藥性細菌感染疾病的流行，尤其是碳青黴烯類抗藥性腸桿菌科細菌（CRE）和產超頻譜BETA-內醯胺酶（ESBL）病原體的流行，這些感染給臨床治療帶來了巨大挑戰。醫療相關感染的增加、老年人口的成長（老年人更容易感染複雜感染疾病）以及醫護人員對抗生素抗藥性模式認知的提高，都顯著推動了市場需求。政府為推廣抗生素管理計劃而採取的舉措、對感染疾病監測的大量投資以及對新型抗菌療法的優惠報銷政策，進一步促進了市場成長。此外，新興國家醫院基礎設施的擴建以及用於細菌鑑定的先進診斷技術的日益普及，也為市場擴張做出了貢獻。

然而，市場面臨諸多限制因素，包括抗生素研發成本高昂、抗生素核准監管要求嚴格，以及潛在副作用導致病患依從性有限。其他挑戰還包括替代治療方法的出現、現有抗生素的非專利競爭，以及長期使用抗生素可能導致抗藥性細菌的擔憂。來自醫療系統的價格壓力和有限的市場獨佔期也是限制市場成長的因素。

然而，拓展兒童患者群體、開發用於門診治療的口服製劑、建立製藥公司與研究機構之間的戰略夥伴關係以及開拓尚未開發的地域市場，都蘊藏著巨大的機會。隨著市場參與者尋求滿足全球對有效感染疾病治療的迫切需求，他們日益重視聯合療法、感染管理中的個人化醫療方法以及不斷增加的抗生素研發投入，這些都代表著巨大的成長潛力。

本報告的主要特點

本報告對全球頭孢他啶和阿維巴坦市場進行了詳細分析，並以 2024 年為基準年，給出了預測期（2025-2032 年）的市場規模和復合年成長率。
它還重點介紹了各個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
它還提供了有關市場促進因素、限制因素和機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的關鍵見解。
全球頭孢他啶和阿維巴坦市場的主要企業已根據以下參數進行了分析，例如公司概況、產品系列、主要亮點、財務績效和策略。
本報告提供的見解將使負責人和公司經營團隊能夠就未來的產品發布、產品更新、市場擴張和行銷策略做出明智的決策。
《全球頭孢他啶阿維巴坦市場》報告針對該行業的各類相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員可以透過各種策略矩陣來分析全球頭孢他啶阿維巴坦市場，從而更輕鬆地做出決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太地區
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
非洲
- 南非
- 北非
- 中非

第11章競爭格局

Pfizer
Allergan
AbbVie
Merck &Co
Cipla
Aurobindo Pharma
Sun Pharmaceutical Industries
Lupin Pharmaceuticals
Hikma Pharmaceuticals
Sandoz
Fresenius Kabi
Dr Reddy's Laboratories
Zydus Lifesciences
Baxter International
Teva Pharmaceutical Industries

第12章分析師建議

機會
分析師觀點
Coherent Opportunity Map (COM)

第13章參考文獻與分析方法

參考
分析方法
關於 Coherent Market Insights

簡介目錄

Product Code: CMI9055

Ceftazidime Avibactam Market is estimated to be valued at USD 3.43 Bn in 2025 and is expected to reach USD 5.92 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.1% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 3.43 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	8.10%	2032 Value Projection:	USD 5.92 Bn

The global ceftazidime avibactam market represents a critical segment within the advanced antimicrobial therapeutics landscape, addressing the growing challenge of multidrug-resistant bacterial infections. Ceftazidime Avibactam, a novel combination antibiotic comprising ceftazidime (a third-generation cephalosporin) and avibactam (a beta-lactamase inhibitor), has emerged as a breakthrough treatment option for complicated intra-abdominal infections, complicated urinary tract infections, and hospital-acquired pneumonia caused by gram-negative bacteria.

This innovative therapeutic combination demonstrates enhanced efficacy against carbapenem-resistant Enterobacteriaceae and other extended-spectrum beta-lactamase producing organisms, positioning it as a vital tool in combating antimicrobial resistance. The market encompasses various formulations, dosage strengths, and distribution channels across hospital pharmacies, retail pharmacies, and online platforms. With increasing prevalence of healthcare-associated infections, rising awareness about antibiotic stewardship programs, and growing investment in antimicrobial research and development, the ceftazidime avibactam market continues to expand globally. Key market participants focus on strategic collaborations, regulatory approvals, and market penetration strategies to capitalize on the substantial unmet medical need in treating resistant bacterial infections, particularly in intensive care units and immunocompromised patient populations.

Market Dynamics

The global ceftazidime avibactam market is primarily driven by the escalating prevalence of multidrug-resistant bacterial infections worldwide, particularly carbapenem-resistant Enterobacteriaceae (CRE) and extended-spectrum beta-lactamase (ESBL) producing pathogens that pose significant therapeutic challenges in clinical settings. The increasing incidence of healthcare-associated infections, rising geriatric population susceptible to complex infections, and growing awareness among healthcare professionals about antimicrobial resistance patterns fuel market demand significantly. Government initiatives promoting antimicrobial stewardship programs, substantial investments in infectious disease research, and favorable reimbursement policies for novel antimicrobial therapies further accelerate market growth. Additionally, expanding hospital infrastructure in emerging economies and increasing adoption of advanced diagnostic techniques for bacterial identification contribute to market expansion.

However, the market faces considerable restraints including high development costs associated with antimicrobial drug discovery, stringent regulatory requirements for antibiotic approvals, and potential side effects leading to limited patient compliance. The emergence of alternative treatment modalities, generic competition from existing antibiotics, and concerns regarding antibiotic resistance development with prolonged usage pose additional challenges. Price pressures from healthcare systems and limited market exclusivity periods further constrain market growth.

Nevertheless, significant opportunities exist through expanding applications in pediatric populations, development of oral formulations for outpatient treatment, strategic partnerships between pharmaceutical companies and research institutions, and penetration into untapped geographical markets. The growing focus on combination therapies, personalized medicine approaches in infectious disease management, and increasing investment in antimicrobial research present substantial growth prospects for market players seeking to address the critical global need for effective anti-infective treatments.

Key Features of the Study

This report provides in-depth analysis of the global ceftazidime avibactam market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global ceftazidime avibactam market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Pfizer, Allergan, AbbVie, Merck & Co., Cipla, Aurobindo Pharma, Sun Pharmaceutical Industries, Lupin Pharmaceuticals, Hikma Pharmaceuticals, Sandoz, Fresenius Kabi, Dr. Reddy's Laboratories, Zydus Lifesciences, Baxter International, and Teva Pharmaceutical Industries.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global ceftazidime avibactam market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ceftazidime avibactam market

Market Segmentation

Type Insights (Revenue, USD Bn, 2020 - 2032)
- Combination (CAZ/AVI)
- Ceftazidime (CAZ)
- Avibactam (AVI)
Indication Insights (Revenue, USD Bn, 2020 - 2032)
- Complicated intra-abdominal infections
- Complicated urinary tract infections
- Hospital-acquired bacterial pneumonia
- Ventilator-associated bacterial pneumonia
- Bloodstream infections caused by carbapenem-resistant organisms
- Other multidrug-resistant Gram-negative infections
Dosage Form Insights (Revenue, USD Bn, 2020 - 2032)
- Injectable
- Powder for Reconstitution
- Pre-filled Syringes
Drug Type Insights (Revenue, USD Bn, 2020 - 2032)
- Branded
- Generic
End User Insights (Revenue, USD Bn, 2020 - 2032)
- Tertiary-care hospitals
- Secondary-care hospitals
- Long-term acute-care facilities
- Specialized infectious disease centers
Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Pfizer
- Allergan
- AbbVie
- Merck & Co
- Cipla
- Aurobindo Pharma
- Sun Pharmaceutical Industries
- Lupin Pharmaceuticals
- Hikma Pharmaceuticals
- Sandoz
- Fresenius Kabi
- Dr Reddy's Laboratories
- Zydus Lifesciences
- Baxter International
- Teva Pharmaceutical Industries

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Ceftazidime Avibactam Market, By Type
- Global Ceftazidime Avibactam Market, By Indication
- Global Ceftazidime Avibactam Market, By Dosage Form
- Global Ceftazidime Avibactam Market, By Drug Type
- Global Ceftazidime Avibactam Market, By End User
- Global Ceftazidime Avibactam Market, By Distribution Channel
- Global Ceftazidime Avibactam Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Ceftazidime Avibactam Market, By Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Combination (CAZ/AVI)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Ceftazidime (CAZ)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Avibactam (AVI)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Ceftazidime Avibactam Market, By Indication, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Complicated intra-abdominal infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Complicated urinary tract infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Hospital-acquired bacterial pneumonia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Ventilator-associated bacterial pneumonia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Bloodstream infections caused by carbapenem-resistant organisms
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Other multidrug-resistant Gram-negative infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Ceftazidime Avibactam Market, By Dosage Form, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Powder for Reconstitution
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Pre-filled Syringes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Ceftazidime Avibactam Market, By Drug Type, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Branded
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Generic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Ceftazidime Avibactam Market, By End User, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Tertiary-care hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Secondary-care hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Long-term acute-care facilities
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Specialized infectious disease centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Ceftazidime Avibactam Market, By Distribution Channel, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Global Ceftazidime Avibactam Market, By Region, 2020 - 2032, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Dosage Form, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

11. Competitive Landscape

Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Allergan
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AbbVie
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Cipla
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Aurobindo Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sun Pharmaceutical Industries
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Lupin Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Hikma Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sandoz
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Fresenius Kabi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Dr Reddy's Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Zydus Lifesciences
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Baxter International
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Teva Pharmaceutical Industries
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies